Literature DB >> 29856174

Single brand, fully-covered, self-expandable metal stent for the treatment of benign biliary disease: when should stents be removed?

Benedetto Mangiavillano1,2, Mouen A Khashab3, Leonardo H Eusebi4, Ilaria Tarantino5, Mario Bianchetti6, Rossella Semeraro7, Rinaldo Pellicano8, Mario Traina5, Alessandro Repici9,7.   

Abstract

The two most relevant endoscopic treatable benign biliary diseases (BBD) are benign biliary strictures (BBSs) and biliary leaks (BLs), often associated with high morbidity. The most common endoscopic treatment for biliary strictures involves placement of multiple plastic stents (PSs), with or without balloon dilation, followed by planned exchange of the stents. Thus, there continues to be high interest in pursuing alternative endoscopic approaches that may achieve better results with fewer interventions. In this setting, the use of a fully-covered, self-expandable metal stent (FCSEMS) is an attractive alternative to single or multiple PSs for the treatment of BBDs. A single metal stent can remain in place for a longer period of time before removal; however, the maximum time the stent can be remain in place is still not well defined. The aim of this review is to determine the removal time of the TaeWoong® FCSEMS, placed for BBD. According to our data analysis, considering the absence of loss of the covering of the FCSEMS and of any adverse events during and after stent removal, leaving the TaeWoong medical FCSEMS in situ for an 8 months' period seems to be acceptable for benign biliary diseases. Further studies need to evaluate their removability at 1 year.

Entities:  

Mesh:

Year:  2018        PMID: 29856174     DOI: 10.23736/S1121-421X.18.02506-0

Source DB:  PubMed          Journal:  Minerva Gastroenterol Dietol        ISSN: 1121-421X


  1 in total

1.  Common bile duct obstruction palliated with common bile duct re-implantation (choledochoduodenostomy) in a cat.

Authors:  Galina Hayes; Sacha Devereux; John P Loftus; Mason Jager; Gerald Duhamel; Tracy Stokol
Journal:  Can Vet J       Date:  2019-10       Impact factor: 1.008

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.